FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936167073> ?p ?o ?g. }

• W2936167073 abstract "Objective: Toll-like receptor-3 agonist Poly-ICLC has been known to activate immune cells and induce HIV replication in pre-clinical experiments. In this study we investigated if Poly-ICLC could be used for disrupting HIV latency while simultaneously enhancing innate immune responses. Design: This was a randomized, placebo-controlled, double-blinded trial in aviremic, cART-treated HIV-infected subjects. Participants (n=15) were randomized 3:1 to receive two consecutive daily doses of Poly-ICLC (1.4mg subcutaneously) versus placebo. Subjects were observed for adverse events, immune activation and viral replication. Methods: Besides primary outcomes of safety and tolerability, several longitudinal immune parameters were evaluated including immune cell phenotype and function via flowcytometry, ELISA and transcriptional profiling. PCR assays for plasma HIV-1 RNA, CD4+ T cell-associated HIV-1 RNA and proviral DNA were performed to measure HIV reservoirs and latency. Results: Poly-ICLC was overall safe and well-tolerated. Poly-ICLC-related adverse events were Grade 1/2, with the exception of one Grade 3 neutropenia which was short-lived. Mild Injection site reactions were observed in nearly all participants in the Poly-ICLC arm. Transcriptional analyses revealed upregulation of innate immune pathways in PBMCs following Poly-ICLC treatment, including strong interferon signaling accompanied by transient increases in circulating IP-10 (CXCL10) levels. These responses generally peaked by 24-48 hours after the first injection and returned to baseline by day 8. CD4+ T cell number and phenotype were unchanged, plasma viral control was maintained and no significant effect on HIV reservoirs was observed. Conclusions: These finding suggest that Poly-ICLC could be safely used for inducing transient innate immune responses in treated HIV+ subjects indicating promise as an adjuvant for HIV therapeutic vaccines. Trial Registration: ClinicalTrials.gov identifier: NCT02071095." @default.
• W2936167073 created "2019-04-25" @default.
• W2936167073 creator A5005110163 @default.
• W2936167073 creator A5022765571 @default.
• W2936167073 creator A5046039848 @default.
• W2936167073 creator A5050196572 @default.
• W2936167073 creator A5051838716 @default.
• W2936167073 creator A5055358847 @default.
• W2936167073 creator A5090472768 @default.
• W2936167073 creator A5091075235 @default.
• W2936167073 creator A5091736003 @default.
• W2936167073 creator A5036716723 @default.
• W2936167073 date "2019-04-09" @default.
• W2936167073 modified "2023-10-16" @default.
• W2936167073 title "Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial" @default.
• W2936167073 cites W1195954943 @default.
• W2936167073 cites W1744273349 @default.
• W2936167073 cites W1968475791 @default.
• W2936167073 cites W1969954098 @default.
• W2936167073 cites W1975768197 @default.
• W2936167073 cites W1985061582 @default.
• W2936167073 cites W1987424341 @default.
• W2936167073 cites W2005764911 @default.
• W2936167073 cites W2009755744 @default.
• W2936167073 cites W2048656672 @default.
• W2936167073 cites W2049978867 @default.
• W2936167073 cites W2055796578 @default.
• W2936167073 cites W2063125566 @default.
• W2936167073 cites W2089238809 @default.
• W2936167073 cites W2092074459 @default.
• W2936167073 cites W2096139318 @default.
• W2936167073 cites W2100262165 @default.
• W2936167073 cites W2106119498 @default.
• W2936167073 cites W2109445380 @default.
• W2936167073 cites W2110887983 @default.
• W2936167073 cites W2111052723 @default.
• W2936167073 cites W2112002812 @default.
• W2936167073 cites W2113863168 @default.
• W2936167073 cites W21160854 @default.
• W2936167073 cites W2117962018 @default.
• W2936167073 cites W2123063882 @default.
• W2936167073 cites W2135814503 @default.
• W2936167073 cites W2140738072 @default.
• W2936167073 cites W2142151289 @default.
• W2936167073 cites W2144926720 @default.
• W2936167073 cites W2147557533 @default.
• W2936167073 cites W2150944106 @default.
• W2936167073 cites W2154912426 @default.
• W2936167073 cites W2156313733 @default.
• W2936167073 cites W2159059319 @default.
• W2936167073 cites W2171156044 @default.
• W2936167073 cites W2277732086 @default.
• W2936167073 cites W2301318199 @default.
• W2936167073 cites W2330556169 @default.
• W2936167073 cites W2340444741 @default.
• W2936167073 cites W2340622963 @default.
• W2936167073 cites W2417934743 @default.
• W2936167073 cites W2464524003 @default.
• W2936167073 cites W2507505058 @default.
• W2936167073 cites W2514351305 @default.
• W2936167073 cites W2553545593 @default.
• W2936167073 cites W2572603768 @default.
• W2936167073 cites W2586226836 @default.
• W2936167073 cites W2586856108 @default.
• W2936167073 cites W2593700719 @default.
• W2936167073 cites W2736882583 @default.
• W2936167073 cites W2752198291 @default.
• W2936167073 cites W2758263899 @default.
• W2936167073 cites W2759688294 @default.
• W2936167073 cites W2771147459 @default.
• W2936167073 cites W2782566786 @default.
• W2936167073 cites W2784346742 @default.
• W2936167073 cites W2802298459 @default.
• W2936167073 cites W2807176127 @default.
• W2936167073 cites W2809886276 @default.
• W2936167073 cites W2883329573 @default.
• W2936167073 cites W2885298105 @default.
• W2936167073 cites W81268756 @default.
• W2936167073 doi "https://doi.org/10.3389/fimmu.2019.00725" @default.
• W2936167073 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6467168" @default.
• W2936167073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31024557" @default.
• W2936167073 hasPublicationYear "2019" @default.
• W2936167073 type Work @default.
• W2936167073 sameAs 2936167073 @default.
• W2936167073 citedByCount "47" @default.
• W2936167073 countsByYear W29361670732019 @default.
• W2936167073 countsByYear W29361670732020 @default.
• W2936167073 countsByYear W29361670732021 @default.
• W2936167073 countsByYear W29361670732022 @default.
• W2936167073 countsByYear W29361670732023 @default.
• W2936167073 crossrefType "journal-article" @default.
• W2936167073 hasAuthorship W2936167073A5005110163 @default.
• W2936167073 hasAuthorship W2936167073A5022765571 @default.
• W2936167073 hasAuthorship W2936167073A5036716723 @default.
• W2936167073 hasAuthorship W2936167073A5046039848 @default.
• W2936167073 hasAuthorship W2936167073A5050196572 @default.
• W2936167073 hasAuthorship W2936167073A5051838716 @default.
• W2936167073 hasAuthorship W2936167073A5055358847 @default.
• W2936167073 hasAuthorship W2936167073A5090472768 @default.
• W2936167073 hasAuthorship W2936167073A5091075235 @default.

• next